Tularemia in central anatolia

Infection

Volumn 41, Issue 2, 2013, Pages 391-399

  Ulu Kilic, A ^a   Gulen, G ^b   Sezen, F ^c   Kilic, S ^c   Sencan, I ^b  

^a Erciyes School of Medicine   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Public Health Institute of Turkey   (Turkey)

Author keywords

Central Turkey; Ciprofloxacin; Tularemia; US findings

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBODY; C REACTIVE PROTEIN; CIPROFLOXACIN; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DRUG EFFICACY; ECHOGRAPHY; EPIDEMIC; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FRANCISELLA TULARENSIS; GERMANY; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; NECROSIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; SURGICAL DRAINAGE; THROAT CULTURE; TREATMENT FAILURE; TREATMENT RESPONSE; TULAREMIA; ULTRASOUND SCANNER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BIOPSY, FINE-NEEDLE; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CIPROFLOXACIN; DOXYCYCLINE; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEASONS; TREATMENT OUTCOME; TULAREMIA; TURKEY; YOUNG ADULT;

EID: 84879493408     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0355-1     Document Type: Article

References (26)

1. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev. 2002;15:631-46.
2. Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci. 2007;1105:1-29.
3. Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci. 2007;1105:378-404.
4. KIlIç S. A general overview of Francisella tularensis and the epidemiology of tularemia in Turkey. Flora Derg. 2010;15:37-58.
5. Reintjes R, Dedushaj I, Gjini A, et al. Tularemia outbreak investigation in Kosovo: case control and environmental studies. Emerg Infect Dis. 2002;8:69-73.
6. Chitadze N, Kuchuloria T, Clark DV, et al. Water-borne outbreak of oropharyngeal and glandular tularemia in Georgia: investigation and follow-up. Infection. 2009;37:514-21.
7. Kantardjiev T, Ivanov I, Velinov T, et al. Tularemia outbreak, Bulgaria, 1997-2005. Emerg Infect Dis. 2006;12:678-80.
8. Akalin H, Helvaci S, Gedikoǧlu S. Re-emergence of tularemia in Turkey. Int J Infect Dis. 2009;13:547-51.
9. Helvaci S, Gedikoǧlu S, Akalin H, Oral HB. Tularemia in Bursa, Turkey: 205 cases in ten years. Eur J Epidemiol. 2000;16:271-6.
10. Gürcan S, Otkun MT, Otkun M, Arikan OK, Ozer B. An outbreak of tularemia in Western Black Sea region of Turkey. Yonsei Med J. 2004;45:17-22.
11. Karadenizli A, Gurcan S, Kolayli F, Vahaboglu H. Outbreak of tularaemia in Golcuk, Turkey in 2005: report of 5 cases and an overview of the literature from Turkey. Scand J Infect Dis. 2005;37:712-6.
12. Celebi G, Baruönü F, Ayoǧlu F, et al. Tularemia, a reemerging disease in Northwest Turkey: epidemiological investigation and evaluation of treatment responses. Jpn J Infect Dis. 2006;59:229-34.
13. Willke A, Meric M, Grunow R, et al. An outbreak of oropharyngeal tularaemia linked to natural spring water. J Med Microbiol. 2009;58:112-6.
14. Ulu KIlIç A, KIlIç S, Sencan I, et al. A water-borne tularemia outbreak caused by Francisella tularensis subspecies holarctica in Central Anatolia region. Mikrobiyol Bul. 2011;45:234-47.
15. Sjöstedt A, Kuoppa K, Johansson T, Sandström G. The 17 kda lipoprotein and encoding gene of Francisella tularensis lvs are conserved in strains of Francisella tularensis. Microb Pathog. 1992;13:243-9.
16. Khanna R, Sharma AD, Khanna S, Kumar M, Shukla RC. Usefulness of ultrasonography for the evaluation of cervical lymphadenopathy. World J Surg Oncol. 2011;9:29.
17. Ahuja AT, Ying M. Sonographic evaluation of cervical lymph nodes. AJR Am J Roentgenol. 2005;184:1691-9.
18. Cutler SJ, Fooks AR, van der Poel WH. Public health threat of new, reemerging, and neglected zoonoses in the industrialized world. Emerg Infect Dis. 2010;16:1-7.
19. Coker R, Rushton J, Mounier-Jack S, et al. Towards a conceptual framework to support one-health research for policy on emerging zoonoses. Lancet Infect Dis. 2011;11:326-31.
20. Tärnvik A, Priebe HS, Grunow R. Tularaemia in Europe: an epidemiological overview. Scand J Infect Dis. 2004;36:350-5.
21. Meric M, Willke A, Finke EJ, et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS. 2008;116:66-73.
22. Tärnvik A. WHO Guidelines on Tularaemia. WHO/CDS/EPR/2007.7. Geneva: World Health Organization (WHO), 2007. http://www.who.int/csr/resources/ publications/WHO-CDS-EPR-2007-7.pdf.
23. Maurin M, Pelloux I, Brion JP, Del Banõ JN, Picard A. Human tularemia in France, 2006-2010. Clin Infect Dis. 2011;53:e133-41.
24. Hepburn MJ, Simpson AJ. Tularemia: current diagnosis and treatment options. Expert Rev Anti Infect Ther. 2008;6:231-40.
25. Yesilyurt M, Kiliç S, Celebi B, et al. Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey. J Antimicrob Chemother. 2011;66:2588-92.
26. Coşkun O, Erdem H, Avci A. Management of community-acquired acute bacterial cystitis in Turkey. Turk J Med Sci. 2011;41:149-57.